Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53

Molecular Cancer Research

Volumn 3, Issue 10, 2005, Pages 563-574

  Zhang, Zhongqiu ^a   Yao, Ruisheng ^a   Li, Jie ^a   Wang, Yian ^a   Boone, Charles W ^b   Lubet, Ronald A ^b   You, Ming ^a  

^a USA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BENZO[A]PYRENE; CYTOSINE; GUANINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAS PROTEIN; THYMINE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CELL CYCLE; CONTROLLED STUDY; CROSS BREEDING; DNA MICROARRAY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; PAPILLOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UNINDEXED SEQUENCE;

ANIMALS; BENZO(A)PYRENE; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; COCARCINOGENESIS; FEMALE; GENES, P53; GENES, RAS; GERM-LINE MUTATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PAPILLOMA; SKIN NEOPLASMS;

ANIMALIA; MUS MUSCULUS;

EID: 27644506100     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0144     Document Type: Article

References (35)

1. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344:975-83.
2. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003;21:217-28.
3. Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy HN. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 1991;4:445-9.
4. Kemp CJ, Burns PA, Brown K, Nagase H, Balmain A. Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Cold Spring Harb Symp Quant Biol 1994;59:427-34.
5. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci U S A 1990;87:538-42.
6. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Klein-Szanto AJ. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci 1993;90:1013-7.
7. Linardopoulos S, Street AJ, Quelle DE, et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res 1995;55:5168-72.
8. Kemp CJ, Fee F, Balmain A. Allelotype analysis of mouse skin tumors using polymorphic microsatellites: sequential genetic alterations on chromosomes 6, 7, and 11. Cancer Res 1993;53:6022-7.
9. Sato H, Suzuki JS, Tanaka M, Ogiso M, Tohyama C, Kobayashi S. Gene expression in skin tumors induced in hairless mice by chronic exposure to ultraviolet B irradiation. Photochem Photobiol 1997;65:908-14.
10. 4 integrin is altered in pre-malignant skin tumors of p53-deficient mice. Int J Cancer 1996;65:254-62.
11. Robles Al, Conti CJ. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis 1995;16:781-6.
12. Mitsunaga SI, Zhang SY, Ruggeri BA, et al. Positive immunohistochemical staining of p53 and cyclin D in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a]pyrene. Carcinogenesis 1995;16:1629-35.
13. Spalding JW, Momma J, Elwell MR, Tennant RW. Chemically induced skin carcinogenesis in a transgenic mouse line (TG AC) carrying a v-Ha-ras gene. Carcinogenesis 1993;14:1335-41.
14. Hansen LA, Spalding JW, French JE, Tennant RW. A transgenic mouse model (TG AC) for skin carcinogenesis: inducible transgene expression as a second critical event. Prog Clin Biol Res 1995;391:223-35.
15. Spalding JW, French JE, Tice RR, Furedi-Machacek M, Haseman JK, Tennant RW. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg AC mice. Toxicol Sci 1999;49:241-54.
16. Li G, Ho VC, Berean K, Tron VA. Ultraviolet radiation induction of squamous cell carcinomas in p53 transgenic mice. Cancer Res 1995;55:2070-4.
17. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
18. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990;250:113-6.
19. Wei SJ, Chang RL, Merkler KA, et al. Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyyrene. Carcinogenesis 1999;20:1689-96.
20. Greenblatt MS, Bennett WP, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
21. Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996;104:435-9.
22. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
23. Evens SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997;3:309-95.
24. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 1997;76:1-14.
25. Hisada M, Garber JE, Fung CY, Fraumeni JF, Jr., Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
26. Zhang Z, Liu Q, Lantry LE, et al. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or Adriamycin. Cancer Res 2000;60:901-7.
27. Zhang Z, Li J, Lantry LE, et al. p53 transgenic mice are highly susceptible to 1,2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002;62:3024-9.
28. Lubet RA, Zhang Z, Wiseman RW, You M. Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 2000;26:581-93.
29. Zhang Z, Wang Y, Lantry LE, et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf Oncogene 2003;18:6257-65.
30. Leder A, Kuo A, Cardiff RD, Sinn E, Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci U S A 1990;87:9178-82.
31. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988;41:178-83.
32. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62.
33. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001;29:25-33.
34. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
35. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002;31:19-20.